Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults | Zendy

Lianpan Dai | Zendy; Lidong Gao | Zendy; Lifeng Tao | Zendy; Sri Rezeki Hadinegoro | Zendy; Musabaev Erkin | Zendy; Zhifang Ying | Zendy; Peng He | Zendy; Rodman T. Girsang | Zendy; Hugo Vergara | Zendy; Javed Akram | Zendy; Hindra Irawan Satari | Zendy; Tanwir Khaliq | Zendy; Ume Sughra | Zendy; Ana P. Celi | Zendy; Fangjun Li | Zendy; Yan Li | Zendy; Zhiwei Jiang | Zendy; Dilbar Dalimova | Zendy; Jaloliddin Tuychiev | Zendy; Shahlo Turdikulova | Zendy; Aamer Ikram | Zendy; Nancy Flores Lastra | Zendy; Fan Ding | Zendy; Mahendra Suhardono | Zendy; Eddy Fadlyana | Zendy; Jinghua Yan | Zendy; Zhongyu Hu | Zendy; Changgui Li | Zendy; Ibrokhim Y. Abdurakhmonov | Zendy; George F. Gao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults

Author(s) -

Lianpan Dai,

Lidong Gao,

Lifeng Tao,

Sri Rezeki Hadinegoro,

Musabaev Erkin,

Zhifang Ying,

Peng He,

Rodman T. Girsang,

Hugo Vergara,

Javed Akram,

Hindra Irawan Satari,

Tanwir Khaliq,

Ume Sughra,

Ana P. Celi,

Fangjun Li,

Yan Li,

Zhiwei Jiang,

Dilbar Dalimova,

Jaloliddin Tuychiev,

Shahlo Turdikulova,

Aamer Ikram,

Nancy Flores Lastra,

Fan Ding,

Mahendra Suhardono,

Eddy Fadlyana,

Jinghua Yan,

Zhongyu Hu,

Changgui Li,

Ibrokhim Y. Abdurakhmonov,

George F. Gao

Publication year - 2022

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2202261

Subject(s) - covid-19 , adjuvant , coronavirus , medicine , clinical trial , d dimer , safety profile , dimer , virology , adverse effect , chemistry , disease , infectious disease (medical specialty) , outbreak , organic chemistry

The ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an adjuvant, was shown to be safe, with an acceptable side-effect profile, and immunogenic in adults in phase 1 and 2 clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research